

TURNING PATIENT CARE
INSIDEOUT

H.C. Wainwright BIOCONNECT Virtual Conference

January 10 – 13, 2022

scPharmaceuticals

*Innovative outpatient solutions that
bring care closer to home*



Disclaimer

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our launch and commercialization plans, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding business strategy, product approval, current and prospective collaborations, timing and likelihood of success, expectations regarding market acceptance and size, plans for launch and commercialization, plans and objectives of management for future operations, the company's financial position and future results of anticipated product candidates, are forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements regarding the FDA's review requirements, the planned resubmission of the FUROSCIX NDA, including potential timing of the resubmission, the ability of the FUROSCIX Infusor to appropriately deliver therapy, the receipt of regulatory approval for FUROSCIX Infusor or any of our other product candidates or, if approved, the successful commercialization of such products, including market acceptance and expected payer cost savings, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates, and the risk that the current COVID-19 pandemic will impact the Company's planned Phase 4 study of FUROSCIX, and other operations and the Company's projected financial guidance. For a discussion of other risks and uncertainties, and other important factors, see the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as other risks detailed in the Company's subsequent filings with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Investment Highlights

Advancing patient care and reducing healthcare costs through innovative subcutaneous delivery

- Two late-stage programs addressing multi billion-dollar markets
 - FUROSCIX® for Heart Failure (HF)
 - A \$5.9B total US market opportunity
 - PDUFA date targeted for Q3 2022
 - scCeftriaxone, a potentially novel delivery of a broad-spectrum antibiotic
 - A \$4.5B total US market opportunity
- Clear value proposition and established-reimbursement model for FUROSCIX
- Well defined development plan leveraging FDA's 505(b)(2) pathway
- Strong intellectual property coverage for FUROSCIX through 2034
- Strong financial position with cash, cash equivalents, restricted cash and investments of \$85.0 million as of September 30, 2021

Senior Management and Board of Directors

John H. Tucker

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Michael Hassman

SENIOR VICE PRESIDENT, OPERATIONS

John Mohr, Pharm. D.

SENIOR VICE PRESIDENT, CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Rachael Nokes

SENIOR VICE PRESIDENT, FINANCE

Board of Directors

William Abraham, MD

Professor of Internal Medicine
(Cardiology), Ohio State
University

Mette Kristine Agger

Lundbeckfond Ventures

Minnie Baylor-Henry

B-Henry & Associates, J&J

Sara Bonstein

CFO Insmed Incorporated

Fred Hudson

Former partner, KPMG

Jack Khattar

CEO, Supernus Pharmaceuticals

Leonard Schaeffer

Founding Chairman & CEO,
WellPoint

Klaus Veitinger, MD, PhD

OrbiMed Advisors

John H. Tucker

CEO, scPharmaceuticals


Large Unmet Need in Heart Failure (HF)

Lead program targets HF — a large global market opportunity with a clear value proposition

- Prevalence of HF is 7.2 million adults in the US¹ and 15.8 million adults in the G7¹
- In the US 4.0 million HF events occur annually^{1,2,3}
 - Congestion is the most common cause of hospitalization⁴
- \$5.9B accessible market opportunity in the US
- HF patients represent 33% (\$123B) of annual Medicare Part A and B spending⁵
- Potential for significant cost savings for payers and hospitals by reducing patient hospital admission/readmission rates

1. Decision Resource Group Report 2020 HF Disease Landscape & Forecast, Table 6 pg 52: forecast of ~3.3M diagnosed events of Acute HF in the US for 2022 and HF prevalence of 7.2M cases note: G7=US, Germany, France, UK, Italy, Spain, Japan equals 15.8M cases .2. Virani, et. al. Circulation 2020;e374 HF clinic visits. 3. Data on file. scPharmaceuticals, Burlington, MA. 4. Mullens W, et al. Eur J Heart Fail 2019; 21(2):137-155. 5. Fitch, et al. Cost Burden of Worsening Heart Failure in the Medicare fee for service population, Milliman, 2017. <http://us.milliman.com/insight/2017/The-cost-burden-of-worsening-heart-failure-in-the-Medicare-fee-for-service-population-An-actuarial-analysis/>

HF Patients are a Significant Financial Burden to Medicare




HF patients represent 33% (\$123B) of annual Medicare Part A and B spending¹

Average cost of a heart failure hospitalization is \$11,840¹

80% of HF costs is attributed to the hospitalization cost¹

Opportunity to decrease medical costs associated with HF treatment



1. Fitch K, et al (2017) The cost burden of worsening heart failure in the Medicare fee for service population: an actuarial analysis [white paper]

Cycle of Decompensation and Hospitalization is the Primary Burden for Patients Suffering from HF

Stable patient treated
with oral diuretic

Fluid retention (Congestion) –
hallmark of HF

Decompensation leads to
↓ oral bioavailability diuretics

Worsening symptoms is the most
common reason patients contact
their provider


Hospitalized patient
treated with IV diuretic

59% of hospital admission
directly attributed to volume
overload¹

Up to 50% of HF hospital
admissions may be avoidable²

30 – 50% patients discharged still
congested³⁻⁵


25-30% of patients readmitted to
the hospital after discharge
within 30 days^{6,7}



1. Bennett S, et al. American Journal of Crit Care. 1998;7(3):168-174. 2. Collins et al. J Am Coll Cardiol. 2013 January 15; 61(2): 121-126. 3. Neuenschwander JF, et al. Crit Care Clin. 2007;23(4):737-58. 4. Costanzo MR, et al. Am Heart J. 2007;154(2):267-77. 5. Fonarow GC, et al. JAMA. 2005;293(5):572-80. 6. Kilgore M et al. Risk Manag Healthc Policy. 2017;10:63..7. Fitch K, et al (2017) The cost burden of worsening heart failure in the Medicare fee for service population: an actuarial analysis [white paper]

Primary Opportunities for Intervention in Worsening Heart Failure (WHF)

Pre-admission and post-discharge (readmission) are targeted opportunities for WHF intervention



*WHF: Worsening Heart Failure

A New Model for Treating Heart Failure — FUROSCIX®

FUROSCIX — a Subcutaneous Formulation of Furosemide

Enabling IV-equivalent diuresis at home

- FUROSCIX – Proprietary formulation of furosemide
 - Furosemide is the most widely used oral and parenteral diuretic in treatment of edema associated with congestive heart failure
 - Physiologic pH formulation enables subcutaneous administration; eliminates skin irritation



FUROSCIX Delivery System Incorporates an Easy-to-use On-Body Infusor

Incorporates West Pharmaceutical Services, Inc.'s SmartDose® Gen II 10ml platform technology

Technology is FDA and EMA approved as part of a combination product

- Pre-filled Crystal Zenith® disposable cartridge
- Delivers fixed 80mg sc dose through pre-programmed, biphasic profile (30mg first hour + 12.5mg/hour for next 4 hours)
- Visual, tactile, and audible feedback
- Electromechanical drive
- Patient-centric design
- Wireless connectivity capability




SmartDose® and the external product configuration of West's SmartDose® drug delivery platform are the intellectual property of West Pharmaceutical Services, Inc. or one of its subsidiaries, in the United States and other countries.

Pivotal PK/PD Study (scP-01-002)

Pharmacokinetic Overview

| | FUROSCIX SC 5-hour, 80 mg infusion (n = 15) ^a | IV bolus furosemide 2-40 mg injection (n = 15) ^a |
|--|--|--|
| C_{max}, ng/mL Mean ± SD | 2040 ± 449 | 8580 ± 2540 |
| t_{max}, h Median (min–max) | 4.00 (1.00–5.08) | 2.08 (0.08–2.08) |
| AUC_{last}, h*ng/mL Mean (SD) | 13000 ± 4000 | 13000 ± 4050 |
| AUC_∞, h*ng/mL Mean (SD) | 13100 ± 4010 | 13200 ± 4170 |



Absolute Bioavailability: 99.6% (90% CI: 94.8-104.8%)

^aOne subject was excluded from analysis due to high pre-dose concentration.
Sica DA, Muntendam P, Myers RL, et al. JACC Basic Transl Sci. 2018;3(1):25-34

FUROSCIX — Regulatory Path

- NDA resubmission target – Q1 2022
 - 6-month NDA review
- No additional efficacy, PK ,safety data, human factors or device modifications are required by FDA
- All additional testing of devices will be required to be on devices manufactured on the planned commercial line
- Pre-Approval Inspection required at the West Pharmaceuticals Scottsdale location
 - Triggered by resubmission

:

FREEDOM-HF Top Line Results

FREEDOM-HF

Study Overview

- Goal
 - To evaluate the economic impact of hospital avoidance and safety with management of worsening HF due to congestion in patients initially presenting to the emergency department with FUROSCIX administered outside the hospital setting
- Objectives
 - Compare the differences in healthcare resource utilization and direct medical costs for patients treated with FUROSCIX outside the hospital with matched patients receiving IV furosemide inside the hospital
 - Evaluate the safety of FUROSCIX administered outside the hospital
 - Describe the quality of life and patient satisfaction for patients who receive FUROSCIX outside the hospital
- Study Design
 - Open-label, comparative study with an adaptive sample size
 - 34-75 patients presenting to ED for worsening HF
 - Interim analysis to be conducted after first 10 subjects complete 30-day follow up to confirm sample size.
 - Patients discharged from the ED and received FUROSCIX at home
 - Cost differences derived and calculated based on matched comparators from Truven Health Analytics Database

FREEDOM-HF

Primary Outcome: Healthcare Costs

| Outcome | Furoscix ^[b] (N=24) | Control (N=66) | Difference (95% CI) | P-value ^[a] |
|---|-----------------------------------|----------------------------|--|------------------------|
| HF-related health care costs, mean (SD) | \$2920.30 (7073.20) | \$19,915.60 (10,666.60) | -\$16,995.30 (-22,187.90, -11,802.70) | <0.0001 |
| Overall health care costs, mean (SD) | \$7512.30 (11,905.50) | \$35,352.80 (31,662.00) | -\$27,840.50 (-41,581.10, -14,100.00) | <0.0001 |

Abbreviations: Heart Failure (HF); Standard Deviation (SD)

[a] P-value was obtained from the t-test statistic.

[b] Costs in Furoscix arm does not include a cost for Furoscix

- Analyses of additional secondary endpoints provide additional insights into the clinical effectiveness of FUROSCIX
 - Patients who received FUROSCIX had a median reduction of heart failure peptide biomarkers from study entry (day 0) to first visit (day 2 – 4), and to last visit (day 30), of 42.3% and 28%, respectively (p<0.01)
 - Patients who received FUROSCIX had a 12.8-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) Summary Score 30 days after study entry

FREEDOM-HF


Conclusions

- Use of FUROSCIX allowed for outpatient treatment of HF patients presenting to the ED with worsening congestion despite oral diuretic use
- Initial HF hospitalization was avoided and persisted across the subsequent 30-days
- Significant reduction in 30-day HF related costs compared to matched comparator group
- The most common adverse events with FUROSCIX were infusion site pain, bruising and dizziness

FUROSCIX Commercial Overview

NEW - FUROSCIX Multi-billion-dollar Annual U.S. Market Opportunity

Potential paradigm shift in how HF is treated



Prevention of admissions and readmissions are targeted opportunities for HF intervention

1. Decision Resource Group Report 2020 HF Disease Landscape & Forecast, Table 6 pg 52: forecast of ~3.3M diagnosed events of Acute HF in the US for 2022 and HF prevalence of 7.2M cases 2. Virani, et. al. Circulation 2020;e374 HF clinic visits 3. H-CUP 2017 Inpatient Stays HF principal diagnosis 4. Market Research Data on file. scPharmaceuticals, Burlington, MA

Stakeholders are Aligned on the Need to Reduce Hospitalizations and Treatment Costs



Payer

- Average cost to Medicare for a HF admission is \$11,840¹
- HF is top condition targeted by CMS Hospital Readmission Reduction Program² (HRRP)
- Medicare Advantage plans bear both medical and pharmacy costs



Hospital and HCP

- Average length of stay is 5.2⁴ days with DRG only reimbursing 3.9 days⁵
- Increased financial exposure for hospitals and providers based on readmission penalty risk
- HF in-patient care represents multi-million-dollar loss for targeted hospitals
- HRRP² introduces potential for substantial financial penalties

1. Fitch, et al. Cost Burden of Worsening Heart Failure in the Medicare fee for service population, Milliman, 2017. <http://us.milliman.com/insight/2017/The-cost-burden-of-worsening-heart-failure-in-the-Medicare-fee-for-service-population-An-actuarial-analysis/> 2. Readmission Reduction Program (HRRP) (updated 2018, April 27) Retrieved from <https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html> 3. Quality Payment Program from CMS <https://qpp.cms.gov/> 4. Agency for Healthcare Research and Quality (AHRQ). HCUP National Inpatient Sample (NIS), 2014 5. Data on file. scPharmaceuticals, Burlington, MA.

Positioning and Messages

Positioning:







Only FUROSCIX, a new subcutaneous infusion of furosemide, enables IV-caliber diuresis at home for heart failure patients with reduced responsiveness to oral therapy – breaking the cycle of hospitalization, by regaining control of fluid

- FUROSCIX provides IV-equivalent diuresis at home, when it's needed and where it's wanted, to reduce heart failure hospitalizations and lower costs
- When oral diuretic bioavailability declines, regain fluid control with FUROSCIX treatment at home
- Avoid heart failure admissions and reduce readmissions due to fluid overload by intervening with FUROSCIX at home

FUROSCIX®
(furosemide) 80mg/10mL for
subcutaneous administration

FUROSCIX® is an investigational drug that is not approved for use by any regulatory agency. The safety and effectiveness of FUROSCIX have not been established. All positioning statements are aspirational.


HCPs Have a High Willingness to Prescribe FUROSCIX and a Rapid Time to Adoption

| | |  |  |  |  |  |  |
|-----------------------------------|----------------|---|--|---|---|---|---|
| | Total n=309 | HF Spec n=101 | Card n=51 | NP n=52 | PCP/IM n=52 | ER n=27 | Hosp. n=26 |
| Intent to prescribe | 93% | 93% | 96% | 94% | 88% | 89% | 96% |
| | | | | | | | |
| | n=290 | n=96 | n=49 | n=50 | n=46 | n=25* | n=24* |
| Intent to prescribe within 6 mos. | 80% | 89% | 88% | 86% | 76% | 56% | 54% |
| HCP launch focus | | | | | | | |

*scPharmaceuticals data on file: Reason Research quantitative study (n=309 HCPs)

FUROSCIX HCP Research—Treatment Share¹

Treatment Shares (based on last 2 patients seen)



1. scPharmaceuticals data on file: Reason Research quantitative study (n=309 HCPs)

2. Total = HF Spec, Card, NP and PCP/IM patients; No ER or Hospitalist/ER and Hospitalists were only asked about their last 2 patients, while HF Spec, Cards, NPs, and PCP/IM were asked for their last pre-acute and last post-acute patient/Q71. Assume Product X were available (without insurance coverage issues) for long enough for you to begin prescribing. If you were to treat adult patients with fluid overload with the same characteristics as your last Pre-Acute Patient and your last Post-Acute Patient/Patient 1 and Patient 2, would you change your previous treatment choice to Product X?

Small specialized force can target top hospitals/clinics efficiently

| Decile | # hospitals | % total hospitals | Normalized discharge volume | % normalized discharge volume | Normalized IV Furosemide volume | % normalized Furosemide volume |
|--------|-------------|-------------------|-----------------------------|-------------------------------|---------------------------------|--------------------------------|
| 7 - 10 | 435 | 7% | 36,772 | 37% | 43,815 | 43% |

Covering ~40% of the IV furosemide and HF discharge opportunity requires a sales force size of 40 territories

Launch starts with 6,000 health care providers (HCPs)

~ 150 HCPs and 10 hospitals per territory


Expect spill-over coverage to reach 50% of opportunity from med group reach to non-targeted hospitals and IDN affiliations

*From Sales Force sizing project conducted by consultant Trinity partners

Heart Failure Drug Coverage

- 47 million lives will be covered by Medicare Part D in 2021
- Medicare D will be the predominant payer segment for FUROSCIX® (75%)
- In 2020, 55% of Medicare D lives were covered by PDP plans while 45% were covered under Medicare Advantage plans
- It is anticipated this split will continue to trend toward a 50-50 split in 2021
- 52% of potential patients will have reduced co-pay
 - 42% LIS and Medicaid will have low copays
 - 10% Commercial can use copay offset cards


HF Lives Drug Coverage



Patient Support and Distribution



Distribution Strategy



Financial Snapshot

- September 30, 2021 cash, cash equivalents, restricted cash and investments \$85.0 million
 - Sufficient to fund operations into 2023
- Venture debt - \$20M (SVB and Solar Capital)
 - Term through September 2023
 - Amortization commencing 4Q21
- Shares outstanding on September 30, 2021: 27,355,454

scPharmaceuticals Investment Highlights Summary

Advancing patient care and reducing healthcare costs through innovative subcutaneous delivery

- Two late-stage programs addressing multi billion-dollar markets
 - FUROSCIX for Heart Failure (HF)
 - A \$5.9B total US market opportunity
 - PDUFA date targeted in Q3 2022
 - scCeftriaxone, a potentially novel delivery of a broad-spectrum antibiotic
 - A \$4.5B total US market opportunity
- Clear value proposition and established reimbursement model for FUROSCIX
- Well defined development plan leveraging FDA's 505(b)(2) pathway
- Strong intellectual property coverage for FUROSCIX through 2034
- Strong financial position with cash, cash equivalents, restricted cash and investments of \$85.0 million as of September 30, 2021

TURNING PATIENT CARE
INSIDEOUT



Thank you

scPharmaceuticals

*Innovative outpatient solutions that
bring care closer to home*